Biologic disappoints in hand OA trial

The biologic adalimumab (Humira) has no effect on pain or structural abnormalities in people with erosive hand osteoarthritis, an Australian randomised placebo controlled trial concludes. According to the team of rheumatologists led by Professor Graeme Jones from the Menzies Institute for Medical Research in Tasmania, the findings indicate that TNF-alpha may not be the right ...

Already a member?

Login to keep reading.

© 2021 the limbic